CG
CGC.US Canopy Growth Corp
- Market cap
- USD 252M
- P/E
- -
- P/B
- 0.53x
- ROE
- -17.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Sep 2026.
Is CGC.US undervalued?
Graham numberThe Graham number of Canopy Growth Corp cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Canopy Growth Corp fundamental analysis
No fundamental analysis for Canopy Growth Corp yet.
Canopy Growth Corp stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Canopy Growth Corp
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel. It also provides vaporizers and accessories; dried flower and pre-rolled joints, oil, and vapes and beverages; extracts and concentrates, such as softgel capsules; and ca…
Full company profileCanopy Growth Corp financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Canopy Growth Corp annual financial statements (CAD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 39.9M | 77.9M | 226M | 399M | 547M | 476M | 333M | 297M | 269M | 285M | 325M |
| Gross Profit | 38.7M | 74.2M | 88.9M | -31.7M | 67.0M | -187M | -63.5M | 80.9M | 79.5M | 69.7M | 91.2M |
| Operating Income | -14.1M | -108M | -615M | -1.67B | -1.24B | -1.02B | -2.63B | -229M | -117M | -73.1M | -90.1M |
| EBITDA | -650K | -95.7M | -567M | -1.38B | -450M | -53.0M | -2.88B | -313M | -479M | -188M | -29.4M |
| Net Income | -7.52M | -67.3M | -736M | -1.32B | -1.74B | -310M | -3.28B | -657M | -598M | -263M | -111M |
| EPS | -0.06 | -0.38 | -2.18 | -3.71 | -4.64 | -7.92 | -71 | -8.79 | -5.56 | -0.88 | -0.26 |
| Balance Sheet | |||||||||||
| Total Assets | 678M | 1.44B | 8.73B | 4.82B | 6.82B | 5.61B | 2.44B | 1.30B | 918M | 1.12B | 1.06B |
| Total Liabilities | 62.9M | 194M | 1.49B | 1.18B | 3.20B | 1.98B | 1.68B | 800M | 430M | 421M | 407M |
| Shareholders' Equity | 640M | 1.16B | 6.78B | 3.43B | 3.48B | 3.58B | 758M | 500M | 487M | 698M | 650M |
| Cash & Short-term Investments | 102M | 323M | 4.54B | 1.40B | 2.32B | 1.37B | 773M | 203M | 131M | 371M | 320M |
| Total Debt | 10.3M | 8.42M | 946M | 440M | 1.72B | 1.64B | 1.41B | 668M | 348M | 279M | 281M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -27.1M | -81.5M | -535M | -773M | -466M | -546M | -558M | -282M | -166M | -63.8M | -84.9M |
| Capital Expenditure | 29.5M | 178M | 719M | 722M | 174M | 48.1M | 10.5M | 4.00M | 11.3M | 5.95M | 9.73M |
| Free Cash Flow | -56.6M | -260M | -1.25B | -1.49B | -640M | -594M | -568M | -286M | -177M | -69.8M | -94.6M |
| Ratios | |||||||||||
| ROE | -1.2% | -5.8% | -10.9% | -38.5% | -50.1% | -8.7% | -432.2% | -131.4% | -122.8% | -37.7% | -17.0% |
| ROA | -1.1% | -4.7% | -8.4% | -27.4% | -25.6% | -5.5% | -134.4% | -50.5% | -65.2% | -23.5% | -10.5% |
| Net Profit Margin | -18.9% | -86.3% | -325.3% | -331.3% | -319.2% | -65.2% | -983.7% | -221.2% | -222.4% | -92.4% | -34.0% |
| Debt to Equity | 0.02x | 0.01x | 0.14x | 0.13x | 0.49x | 0.46x | 1.86x | 1.34x | 0.72x | 0.40x | 0.43x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Canopy Growth Corp dividends
Canopy Growth Corp has not paid dividends in the last 9 fiscal years.
Last stock split: 1:10 on Dec 20, 2023.
Who owns Canopy Growth Corp
- Insiders 0.18%
- Institutions 7.53%
- Public & others 92.29%
- Shares outstanding 423M
- Free float 422M
Top funds holding CGC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| ETFMG Alternative Harvest ETF | 8.98M | 2.12% | 0.00% | Oct 2026 |
| Global X Marijuana Life Sciences ETF | 2.82M | 0.67% | -6.79% | Sep 2026 |
| Lazard Baylight US Sm Cap Eq WW Dist EUR | 1.45M | 0.34% | -0.88% | Jul 2026 |
| TD Canadian Equity Index ETF | 560K | 0.13% | +3.70% | Oct 2026 |
| Mackenzie Canadian Equity ETF | 521K | 0.12% | 0.00% | Oct 2026 |
| AdvisorShares Pure Cannabis ETF | 383K | 0.09% | 0.00% | Oct 2026 |
| iShares S&P/TSX Small Cap ETF | 355K | 0.08% | -1.45% | Oct 2026 |
| USA Mutuals Vice Investor | 300K | 0.07% | 0.00% | Jun 2026 |
| CANSOUL Fonds Hanf Aktien Global EUR C | 270K | 0.06% | 0.00% | Sep 2026 |
| Desjardins Canadian Equity Index ETF | 209K | 0.05% | +0.10% | Oct 2026 |
| State Street® SPDR® S&P® Intl Sm Cp ETF | 168K | 0.04% | 0.00% | Oct 2026 |
| TD Canadian Index - I | 161K | 0.04% | 0.00% | Jun 2026 |
| Scotia Canadian Equity Index A | 137K | 0.03% | 0.00% | Jul 2026 |
| DFA Canadian Core Equity Class F | 109K | 0.03% | 0.00% | Aug 2026 |
| Lazard US Systematic Small Cap Eq ETF | 66.1K | 0.02% | -11.16% | Oct 2026 |
| DFA International Core Equity 2 I | 35.5K | 0.01% | 0.00% | Sep 2026 |
| CI Canadian Equity ETF | 26.2K | 0.01% | +1.32% | Sep 2026 |
| State Street® SPDR® Ptf Dev Wld exUS ETF | 22.2K | 0.01% | 0.00% | Oct 2026 |
| LVIP Dimensional Intl Core Eq Std | 7.04K | 0.00% | 0.00% | Sep 2026 |
| Arca Azioni Internazionali P | 367.00 | 0.00% | 0.00% | Aug 2026 |
Top institutions holding CGC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Tidal Investments LLC. | 9.19M | 2.17% | +8.37% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 1.95M | 0.46% | -1.19% | Jun 2026 |
| Lazard Asset Management LLC | 1.85M | 0.44% | +2.19% | Jun 2026 |
| Jane Street Group LLC | 1.56M | 0.37% | -1.23% | Jun 2026 |
| UBS Group AG | 1.40M | 0.33% | +48.64% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.30M | 0.31% | +3.17% | Jun 2026 |
| Susquehanna International Group, LLP | 1.22M | 0.29% | +24.33% | Jun 2026 |
| Royal Bank of Canada | 1.08M | 0.26% | +10.86% | Jun 2026 |
| NATIONAL BANK OF CANADA /FI/ | 858K | 0.20% | +5.98% | Jun 2026 |
| HRT FINANCIAL LLC | 715K | 0.17% | +124.89% | Jun 2026 |
| TD Asset Management Inc | 687K | 0.16% | +34.52% | Jun 2026 |
| SBI Securities Co Ltd | 683K | 0.16% | +10.67% | Jun 2026 |
| Federation des caisses Desjardins du Quebec | 501K | 0.12% | -37.10% | Jun 2026 |
| Millennium Management LLC | 493K | 0.12% | -43.22% | Jun 2026 |
| Mackenzie Investments | 477K | 0.11% | +37.16% | Jun 2026 |
| SIG North Trading, ULC | 465K | 0.11% | 0.00% | Jun 2026 |
| OZ Management LLC | 335K | 0.08% | 0.00% | Jun 2026 |
| AdvisorShares Investments, LLC | 290K | 0.07% | 0.00% | Jun 2026 |
| D. E. Shaw & Co LP | 280K | 0.07% | +392.88% | Jun 2026 |
| Baader Bank INC | 270K | 0.06% | -22.40% | Jun 2026 |
Canopy Growth Corp company profile
- Company name
- Canopy Growth Corp
- Ticker
- CGC.US
- ISIN
- CA1380357048
- Exchange
- USA Stocks
- Listed since
- Apr 4, 2014
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 1,128
- Fiscal year end
- March
- Address
- 1 Hershey Drive, Smiths Falls, ON, Canada, K7A 0A8
- Phone
- 855 558 9333
- Website
- canopygrowth.com
About Canopy Growth Corp
Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and cannabis-related products for medical and adult use in Canada, Germany, the United States, and internationally. The company operates through two segments, Cannabis and Storz & Bickel. It also provides vaporizers and accessories; dried flower and pre-rolled joints, oil, and vapes and beverages; extracts and concentrates, such as softgel capsules; and cannabis edibles, including gummies. In addition, the company operates e-commerce shop; medical cannabis online distribution platform; and an online medical cannabis clinic. It sells its products under the Tweed, 7ACRES, Deep Space, HiWay, Maitri, Twd., Spectrum Therapeutics, Canopy Medical, Abba Medix, Storz & Bickel, Wana, and Claybourne, Apollo, Canada House, R'belle, LowKey, MTL Cannabis, DeeLish, DOJA brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation is headquartered in Smiths Falls, Canada.
Canopy Growth Corp management
10- Mr. Luc MongeauCEO & Director · born 1967
- Mr. Thomas Carlton Stewart CPAChief Accounting Officer & CFO · born 1982
- Dr. Christelle Gedeon L.L.B., Ph.D.Chief Business Development & Corporate Affairs Officer · born 1982
- Ms. Chrissy McHardySenior Vice President of Human Resources
- Jason GreenHead of Agriculture - Hemp Division
- Mr. Andrew BevanPresident of Medical Sales
- Mr. Miles WorneManaging Director of European Markets
- Mr. David MannerManaging Director of Storz & Bickel GmbH
- Mr. Christopher RoachSenior Vice President of Supply Chain & Transformation
- Ms. Megan Amber McCraePresident of Canada Adult Use